Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate
A total of 1,904 women, aged 15-38, used an injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide with 6 mg estradiol enanthate, given once during each menstrual cycle between the 7th and 10th day, and preferably on the 8th day of the cycle, for a total of 17,576 cycles. Of these 1,904 women, 1,197 completed 12 cycles of use of the injectable combination. One subject became pregnant during the trial, resulting in a cumulative pregnancy rate of 0.07%. Principal reasons for discontinuation were personal, non-medical reasons, such as lost to follow-up, no longer wished to continue, protocol violation, desire to change to another contraceptive method, moved away, or other personal reasons. Mean weight of 1,901 subjects at admission to the trial was 53.5 +/- 0.2 kg and this increased to 54.3 +/- 0.3 kg after 12 cycles of use. Approximately 50% of subjects experienced menstrual bleeding similar to normal throughout the study period. The most frequent menstrual abnormality was irregular bleeding, experienced by approximately one-third of subjects.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2000 |
|---|---|
| Erschienen: |
2000 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Contraception - 61(2000), 4 vom: 01. Apr., Seite 277-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coutinho, E M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 11.08.2000 Date Revised 26.08.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM108236536 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM108236536 | ||
| 003 | DE-627 | ||
| 005 | 20231222144735.0 | ||
| 007 | tu | ||
| 008 | 231222s2000 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0361.xml |
| 035 | |a (DE-627)NLM108236536 | ||
| 035 | |a (NLM)10899484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coutinho, E M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate |
| 264 | 1 | |c 2000 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2000 | ||
| 500 | |a Date Revised 26.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A total of 1,904 women, aged 15-38, used an injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide with 6 mg estradiol enanthate, given once during each menstrual cycle between the 7th and 10th day, and preferably on the 8th day of the cycle, for a total of 17,576 cycles. Of these 1,904 women, 1,197 completed 12 cycles of use of the injectable combination. One subject became pregnant during the trial, resulting in a cumulative pregnancy rate of 0.07%. Principal reasons for discontinuation were personal, non-medical reasons, such as lost to follow-up, no longer wished to continue, protocol violation, desire to change to another contraceptive method, moved away, or other personal reasons. Mean weight of 1,901 subjects at admission to the trial was 53.5 +/- 0.2 kg and this increased to 54.3 +/- 0.3 kg after 12 cycles of use. Approximately 50% of subjects experienced menstrual bleeding similar to normal throughout the study period. The most frequent menstrual abnormality was irregular bleeding, experienced by approximately one-third of subjects | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Algestone Acetophenide | |
| 650 | 4 | |a Americas | |
| 650 | 4 | |a Brazil | |
| 650 | 4 | |a Clinical Research | |
| 650 | 4 | |a Comparative Studies | |
| 650 | 4 | |a Contraception | |
| 650 | 4 | |a Contraceptive Agents | |
| 650 | 4 | |a Contraceptive Agents, Estrogen | |
| 650 | 4 | |a Contraceptive Agents, Female | |
| 650 | 4 | |a Contraceptive Agents, Progestin | |
| 650 | 4 | |a Contraceptive Effectiveness | |
| 650 | 4 | |a Contraceptive Methods | |
| 650 | 4 | |a Developing Countries | |
| 650 | 4 | |a Estradiol Enanthate | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Health | |
| 650 | 4 | |a Injectables | |
| 650 | 4 | |a Latin America | |
| 650 | 4 | |a Public Health | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a South America | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Use-effectiveness | |
| 650 | 7 | |a Contraceptive Agents, Female |2 NLM | |
| 650 | 7 | |a Estradiol |2 NLM | |
| 650 | 7 | |a 4TI98Z838E |2 NLM | |
| 650 | 7 | |a Algestone Acetophenide |2 NLM | |
| 650 | 7 | |a OL7KC2O3OT |2 NLM | |
| 650 | 7 | |a estradiol enanthate |2 NLM | |
| 650 | 7 | |a PAP315WZIA |2 NLM | |
| 700 | 1 | |a Spinola, P |e verfasserin |4 aut | |
| 700 | 1 | |a Tomaz, G |e verfasserin |4 aut | |
| 700 | 1 | |a Morais, K |e verfasserin |4 aut | |
| 700 | 1 | |a Nassar de Souza, R |e verfasserin |4 aut | |
| 700 | 1 | |a Sabino Pinho Neto, J |e verfasserin |4 aut | |
| 700 | 1 | |a de Barros Leal, W |e verfasserin |4 aut | |
| 700 | 1 | |a Bomfim Hippolito, S |e verfasserin |4 aut | |
| 700 | 1 | |a D'Aurea Abranches, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contraception |d 1972 |g 61(2000), 4 vom: 01. Apr., Seite 277-80 |w (DE-627)NLM000108367 |x 1879-0518 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2000 |g number:4 |g day:01 |g month:04 |g pages:277-80 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2000 |e 4 |b 01 |c 04 |h 277-80 | ||